Yo-Bio on Twitter: "$TEVA will compete in the risperidone Extended-Release market with $JNJ (risperdal consta- every 2 weeks, INTRAMUSCULAR) and $INDV (PERSERIS- every 4 weeks, subcutaneous). if Teva regimen and efficacy will
Risperidone extended-release injectable suspension | MDedge Psychiatry
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Teva, MedinCell Schizophrenia Drug Delayed over FDA Concerns | BioSpace
Teva's Risperidone Injectable Wards Off Schizophrenia Relapse in Phase III – PharmaLive
Teva Upbeat On Risperidone Results :: Generics Bulletin
Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders | SpringerLink
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
/cloudfront-us-east-2.images.arcpublishing.com/reuters/Q3V76PIRQBKVFCT4F2KKAGPMDE.jpg "Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement | Reuters")
Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement | Reuters
Teva: The Road To Perdition Has Turned Into A Path Towards Redemption (NYSE: TEVA) | Seeking Alpha
Positive Results From Trial of Risperidone Injectable Schizophrenia Treatment
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia - Pharmaceutical Business review
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
Veterans' treatment discontinuation differs by type of antipsychotic
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Buy Teva Pharmaceuticals amid positive news, Bernstein says
